Classification of accelerated phase chronic myeloid leukemia in the era of the <scp>BCR</scp>::<scp>ABL1</scp> tyrosine kinase inhibitors: A work in progress
Hagop M. Kantarjian, Ayalew Tefferi
Abstract
Hagop Kantarjian: Research grants from Novartis, BMS, Takeda, Ascentage Pharma. Ayalew Tefferi: none. Data sharing is not applicable to this article.
Topics & Concepts
Myeloid leukemiaTyrosine kinaseCancer researchMedicineInternal medicineReceptorChronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia ResearchChronic Lymphocytic Leukemia Research